SCHEMBL5453408

SCHEMBL5453408

CCOc1ccc(C=C2C(=O)NN(c3ccccc3)C2=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.68
MEN1 O00255 6/20 0.68
EGFR P00533 1/20 0.59
GAA P10253 5/20 0.58
POLB P06746 4/20 0.58
MAPT P10636 4/20 0.58
ALDH1A1 P00352 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
CASP6 P55212 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
SRC P12931 3/20 0.57
ABL1 P00519 2/20 0.57
NR1H4 Q96RI1 3/20 0.55
ARHGEF12 Q9NZN5 1/20 0.55
LMNA P02545 1/20 0.54
DUSP26 Q9BV47 1/20 0.53
PIM1 P11309 1/20 0.51
PIM2 Q9P1W9 1/20 0.51
GFER P55789 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453405 1.00 KMT2A (0.68) KMT2AMEN1EGFRGAAPOLB
SCHEMBL5448905 0.90 KMT2A (0.65) KMT2AMEN1EGFRGAAPOLB
SCHEMBL5444775 0.90 KMT2A (0.65) KMT2AMEN1EGFRGAAPOLB
SCHEMBL5444779 0.90 KMT2A (0.65) KMT2AMEN1EGFRGAAPOLB
SCHEMBL5448904 0.90 KMT2A (0.65) KMT2AMEN1EGFRGAAPOLB
SCHEMBL15936931 0.86 EGFR (0.72) KMT2AMEN1EGFRSRCABL1
SCHEMBL5445714 0.82 KMT2A (0.61) KMT2AMEN1EGFRGAAPOLB
SCHEMBL5445717 0.82 KMT2A (0.61) KMT2AMEN1EGFRGAAPOLB
SCHEMBL5449380 0.82 POLB (0.78) KMT2AMEN1GAAPOLBMAPT
SCHEMBL5449377 0.82 POLB (0.78) KMT2AMEN1GAAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037846-A1 Pyrazolidinedione derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-15 US claimed
US-20070037846-A1 Pyrazolidinedione derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037846-A1 Pyrazolidinedione derivatives P2RY1, P2RY4, P2RY2 KMT2A 4413/4885MEN1 2963/4885EGFR 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.